You are here

COVID-19

Pfizer’s full-year revenues grow 23%, top $100B

Pfizer’s full-year revenues grow 23%, top $100B

Medical Marketing and Media

Flag link:

FDA to resume in-person formal meetings in February

FDA to resume in-person formal meetings in February

RAPS.org

Flag link:

Pharma reputation drops to pre-pandemic normal, with Pfizer and Moderna falling in the ranks

Pharma reputation drops to pre-pandemic normal, with Pfizer and Moderna falling in the ranks

Medical Marketing and Media

Moderna Therapeutics

Flag link:

WHO extends public health emergency over Covid but signals end could come soon

WHO extends public health emergency over Covid but signals end could come soon

Stat

Flag link:

After 'half-baked' data drop, CureVac releases results on mRNA flu, COVID-19 vaccines in older adults

After 'half-baked' data drop, CureVac releases results on mRNA flu, COVID-19 vaccines in older adults

Fierce Biotech

clinical trials

Flag link:

Following FDA COVID vaccine advisory panel vote, Novavax is prepared to provide a revised vaccine

Following FDA COVID vaccine advisory panel vote, Novavax is prepared to provide a revised vaccine

CP WIre

Flag link:

Following FDA COVID vaccine advisory panel vote, Novavax is prepared to provide a revised vaccine

Flag link:

FDA reports initial 'no signal' for stroke risk with Pfizer boosters, launches concomitant flu shot study

FDA reports initial 'no signal' for stroke risk with Pfizer boosters, launches concomitant flu shot study

Endpoints

bivalent boosters

Flag link:

FDA advisers back agency plan to simplify COVID-19 vaccination

FDA advisers back agency plan to simplify COVID-19 vaccination

BioPharma Dive

Flag link:

FDA yanks EUA for AstraZeneca’s Evusheld as COVID variants continue to evolve

FDA yanks EUA for AstraZeneca’s Evusheld as COVID variants continue to evolve

Medical Marketing and Media

Emergency Use Authorization

Flag link:

BMS settles lawsuit with two fired employees who refused COVID vaccines

BMS settles lawsuit with two fired employees who refused COVID vaccines

Fierce Pharma

Bristol Myers Squibb

Flag link:

Two new studies paint encouraging picture of Covid-19 vaccine’s performance

Two new studies paint encouraging picture of Covid-19 vaccine’s performance

Stat

Flag link:

Moderna now in the crosshairs of Sens. Warren, Welch over price tag for COVID vaccine

Moderna now in the crosshairs of Sens. Warren, Welch over price tag for COVID vaccine

Fierce Pharma

Moderna Therapeutics

Flag link:

Abbott Laboratories Skids As Covid Testing Weighs On Organic Growth

Abbott Laboratories Skids As Covid Testing Weighs On Organic Growth

Investors Business Daily

Flag link:

3 Reasons Why Johnson & Johnson Stock Could Rebound After a Bad Start in 2023

3 Reasons Why Johnson & Johnson Stock Could Rebound After a Bad Start in 2023

Motley Fool

consumer health

foreign exchange rates

Flag link:

Dyadic initiates subject dosing in Phase I trial of Covid-19 booster

Dyadic initiates subject dosing in Phase I trial of Covid-19 booster

Clinical Trials Arena

clinical trials

Flag link:

Axcella Clears Regulatory Path for Long COVID Therapeutic

Axcella Clears Regulatory Path for Long COVID Therapeutic

BioSpace

Axcella Therapeutics

Flag link:

Tevogen Bio reports positive data from Covid-19 T cell therapy trial

Tevogen Bio reports positive data from Covid-19 T cell therapy trial

Clinical Trials Arena

clinical trials

Flag link:

mRNA Covid Shots Safe And Effective In Children Ages 5-11, Large Study Finds—Though Vaccine Uptake Remains Low

mRNA Covid Shots Safe And Effective In Children Ages 5-11, Large Study Finds—Though Vaccine Uptake Remains Low

Forbes

Moderna Therapeutics

Flag link:

FDA considers major shift in COVID vaccine strategy

FDA considers major shift in COVID vaccine strategy

NPR

Flag link:

Pages